October 2, 2023 11:12 AM EDTUpdated 05:19 PM

Novartis to seek accelerated approval for oral complement inhibitor in rare kidney disease

Lei Lei Wu

News Reporter

Novartis said that its experimental complement inhibitor iptacopan reduced the buildup of protein in the urine of patients with IgA nephropathy significantly more than a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis to seek accelerated approval for oral complement inhibitor in rare kidney disease

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Icon's quarterly earnings hit by biotech and pharma pullback

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

No­var­tis to seek ac­cel­er­at­ed ap­proval for oral com­ple­ment in­hibitor in rare kid­ney dis­ease

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Novartis to seek accelerated approval for oral complement inhibitor in rare kidney disease